Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis

5 Nov 2018

Abstract excerpt

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is approved by the Food and Drug Administration for its use as first-line treatment in chronic lymphocytic leukemia (CLL). Despite its efficacy, patients treated with ibrutinib rarely achieve complete responses and usually remain under treatment until progression. Considering the inherent high susceptibility of CLL patients to infections, a better...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Galectins and Cancer Biology
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30397191
DOI: 10.1038/s41408-018-0136-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosisPMID 30397191Read ↗

Role of apoptosis and autophagy in tuberculosisSemantic proximity Read ↗

Invasive Aspergillosis in Patients Treated With IbrutinibSemantic proximity Read ↗

Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological ConsequencesSemantic proximity Read ↗

Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2Semantic proximity Read ↗

Profile of <i>Mycobacterium tuberculosis</i> -specific CD4 T cells at the site of disease and blood in pericardial tuberculosisSemantic proximity Read ↗

Mycobacterium tuberculosis TlyA Protein Negatively Regulates T Helper (Th) 1 and Th17 Differentiation and Promotes Tuberculosis Pathogenesis.Semantic proximity Read ↗

Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against Mycobacterium tuberculosis Infection?Semantic proximity Read ↗

The host-directed therapeutic imatinib mesylate accelerates immune responses to <i>Mycobacterium marinum</i> infection and limits pathology associated with granulomasSemantic proximity Read ↗

DNA hypermethylation during tuberculosis dampens host immune responsivenessSemantic proximity Read ↗

T-cell exhaustion in tuberculosis: pitfalls and prospectsSemantic proximity Read ↗

Comparison of the frequency and phenotypic profile of Mycobacterium tuberculosis-specific CD4 T cells between the site of disease and blood in pericardial tuberculosis.Semantic proximity Read ↗

Recent advances in our understanding of human host responses to tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.